Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. C. Chaumais, F. Perros, M. Molimard, S. Bouchet, P. Dorfmuller, C. Guignabert, S. Cohen-Kaminsky, M. Humbert, D. Montani (Le Plessis Robinson, France). A dose-response study of nilotinib and imatinib in experimental pulmonary hypertension. Eur Respir J 2012; 40: Suppl. 56, 3900

Member's Comments

No comment yet.

Related content which might interest you: Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 New therapeutic approach for the treatment of monocrotaline-induced pulmonary hypertension with imatinib Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020 A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003 Long-term safety and efficacy of imatinib in pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Initial combination of macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension (PAH): results from the OPTIMA study Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Effects of prednisolone and imatinib mesylate on inflammation and fibrosis in amiodarone-induced pulmonary toxicity in rats Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010 Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 469-475 Year: 2007 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study Source: Eur Respir J 2014; 43: 1691-1697 Year: 2014 Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension Source: Eur Respir J 2010; 36: 808-818 Year: 2010 A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010